Novartis's Misstep: What It Says About the High Stakes World of Rare Disease Treatment The pharmaceutical company Novartis has suffered a significant blow with the failure of its del desiran drug in a late stage trial.
The 10% plunge in shares is just the beginning – this setback puts Novartis on track for its worst trading day ever.
Del desiran was touted as a promising treatment for myotonic dystrophy type 1 (DM1), a rare genetic disorder that causes muscle wasting and difficulty opening one's hands.